Credit Suisse’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-140,056
| Closed | -$476K | – | 4089 |
|
|
2018
Q3 | $476K | Sell |
140,056
-27,204
| -16% | -$98.1K | ﹤0.01% | 3325 |
|
|
2018
Q2 | $629K | Sell |
167,260
-761
| -0.5% | -$3.71K | ﹤0.01% | 3308 |
|
|
2018
Q1 | $686K | Buy |
168,021
+43,706
| +35% | +$204K | ﹤0.01% | 3189 |
|
|
2017
Q4 | $578K | Buy |
124,315
+3,445
| +3% | +$19K | ﹤0.01% | 3354 |
|
|
2017
Q3 | $858K | Buy |
120,870
+34,576
| +40% | +$249K | ﹤0.01% | 3210 |
|
|
2017
Q2 | $624K | Sell |
86,294
-80,203
| -48% | -$501K | ﹤0.01% | 3003 |
|
|
2017
Q1 | $1.02M | Buy |
166,497
+88,411
| +113% | +$484K | ﹤0.01% | 2847 |
|
|
2016
Q4 | $457K | Buy |
78,086
+28,195
| +57% | +$154K | ﹤0.01% | 3496 |
|
|
2016
Q3 | $265K | Sell |
49,891
-79,428
| -61% | -$428K | ﹤0.01% | 3701 |
|
|
2016
Q2 | $856K | Sell |
129,319
-22,107
| -15% | -$124K | ﹤0.01% | 3061 |
|
|
2016
Q1 | $707K | Buy |
151,426
+33,875
| +29% | +$135K | ﹤0.01% | 2991 |
|
|
2015
Q4 | $594K | Buy |
117,551
+63,957
| +119% | +$304K | ﹤0.01% | 3238 |
|
|
2015
Q3 | $189K | Sell |
53,594
-53,585
| -50% | -$359K | ﹤0.01% | 3945 |
|
|
2015
Q2 | $1.07M | Buy |
107,179
+71,905
| +204% | +$771K | ﹤0.01% | 3121 |
|
|
2015
Q1 | $449K | Sell |
35,274
-58,262
| -62% | -$749K | ﹤0.01% | 3618 |
|
|
2014
Q4 | $1.32M | Buy |
93,536
+3,397
| +4% | +$52.6K | ﹤0.01% | 2901 |
|
|
2014
Q3 | $1.24M | Sell |
90,139
-5,575
| -6% | -$85.3K | ﹤0.01% | 2867 |
|
|
2014
Q2 | $1.47M | Sell |
95,714
-38,479
| -29% | -$545K | ﹤0.01% | 2965 |
|
|
2014
Q1 | $2.29M | Buy |
134,193
+16,560
| +14% | +$250K | ﹤0.01% | 2408 |
|
|
2013
Q4 | $1.52M | Sell |
117,633
-49,179
| -29% | -$587K | ﹤0.01% | 2916 |
|
|
2013
Q3 | $1.68M | Buy |
166,812
+121,952
| +272% | +$1.09M | ﹤0.01% | 2544 |
|
|
2013
Q2 | $335K | Buy |
+44,860
| New | +$351K | ﹤0.01% | 3563 |
|
Credit Suisse's KERX Position: Q4 2018 in Review
Credit Suisse sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 140,056 shares — an estimated $476K sold.
Credit Suisse first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $2.29M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Credit Suisse reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Credit Suisse sold 140,056 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $476K.
- Credit Suisse first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Credit Suisse's Keryx Biopharmaceuticals Inc position peaked at $2.29M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Credit Suisse's 13F filing for Q4 2018, filed 13 Feb 2019.